CON: Neoadjuvant Therapy Should be Routinely Given for High-risk Intrahepatic Cholangiocarcinoma

Debater(s)

• CF

  Cristina Ferrone, MD (she/her/hers)

  Chair of Surgery
  Cedars-Siani
  Los Angeles, California, United States

  Disclosure(s): Astra Zeneca: Advisor (Terminated, June 30, 2022); Intraop: Advisor (Terminated, November 1, 2022)